The U.S. federal government has reached an agreement to pay pharmaceutical company Pfizer and its German partner BioNTech a total of $3.2 billion for 105 million doses of a covid-19 vaccine, according to a statement from the two companies. The doses are part of a fall campaign to get more people vaccinated in the United States, which has the lowest covid-19 vaccination rate of any wealthy nation.
Pfizer’s large order includes vaccine designed specifically for omicron variant of the disease, but shipmentsf These will be subject to FDA approval, which is currently pending.
“As the virus evolves, this new agreement will help ensure that people across the country have access to vaccines that may provide protection against current and future variants,” said Albert Burra, Pfizer chairman and chief executive officer (Albert Bourla) said in a statement. online.
Pfizer said it expects to begin delivering 105 million doses of the vaccine as early as “late summer” and to push for new vaccinations in the months thereafter. The worry, of course, is that covid-19 could reemerge from already high numbers as the weather cools and more people get indoors.
The United States reported 196,230 new cases and 693 deaths on Wednesday. New York Times, would be considered an unusually high number at any other point in the past two years. But for most Americans who seem to have gotten their bearings, the pandemic is more or less background noise. The U.S. has reported more than 1.01 million deaths from covid-19 and more than 87.4 million cases since the pandemic began.
While some Americans remain deeply concerned about the possibility of dealing with “long-term covid,” the Biden administration has shown no interest in continuing to fight the pandemic in any overt way — at least in any way more enthusiastic than buying a vaccine.Thankfully, according to a recent study, vaccination does appear to cut the risk of long-term Covid-19 infection in half leave the UK.
Only 67.3% of Americans are fully vaccinated against covid-19, according to the latest data from Johns Hopkins University.
“This agreement will provide additional doses to U.S. residents and help combat the next wave of COVID-19. Pending regulatory authorization, it will also include A vaccine for Omicron, which we believe is important to address rapidly spreading Omicron variants.
“We appreciate the continued cooperation of the U.S. government in our shared goal of helping to end this pandemic,” Marrett continued.
as Bloomberg News Note that Pfizer shares rose 0.6% after the close on Wednesday.